Azerbaijan vs Kazakhstan: Pneumococcal conjugate second or third-dose vaccines (PCVc)
Azerbaijan
52.0%
in 2025
Kazakhstan
49.0%
in 2025
Azerbaijan rank
153rd
Kazakhstan rank
154th
Pneumococcal conjugate second or third-dose vaccines (PCVc) over time
- Azerbaijan
- Kazakhstan
How they compare
Azerbaijan currently reports 52.0% against 49.0% in Kazakhstan, a difference of 3.0%.
That makes Azerbaijan's figure about 1.1 times Kazakhstan's.
The two have swapped places 5 times across 18 shared years of data; in 2008 it was Kazakhstan ahead.
Azerbaijan ranks 153rd and Kazakhstan ranks 154th of 192 countries.
Kazakhstan has averaged higher in every one of the 3 decades both report.
Head to head by decade
| Decade | Azerbaijan | Kazakhstan | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 0.0% | 0.0% | 0.0% | — |
| 2010s | 42.0% | 51.4% | 9.4% | Kazakhstan |
| 2020s | 50.8% | 50.8% | 0.0% | — |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher pneumococcal conjugate second or third-dose vaccines (pcvc), Azerbaijan or Kazakhstan?
- Azerbaijan, at 52.0% against 49.0% in Kazakhstan as of 2025.
- What is the difference in pneumococcal conjugate second or third-dose vaccines (pcvc) between Azerbaijan and Kazakhstan?
- 3.0%, with Azerbaijan ahead.
- How many years of comparable data are there for Azerbaijan and Kazakhstan?
- 18 years are reported by both, from 2008 to 2025.
- How do Azerbaijan and Kazakhstan rank globally for pneumococcal conjugate second or third-dose vaccines (pcvc)?
- Azerbaijan ranks 153rd and Kazakhstan ranks 154th of 192 countries.
- Where does this data come from?
- World Health Organization, Global Health Observatory, published as Pneumococcal conjugate second or third-dose vaccines (PCVc) immunization coverage by the locally recommended age (%) (WUENIC). Statizoid refreshes it automatically from the source and publishes the full history for both places.